F. W. Arnold, T. L. Wiemken, P. Peyrani, J. A. Ramirez, and G. N. Brock, Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study, Respir Med. juillet, vol.107, issue.7, pp.1101-1112, 2013.

T. Welte, A. Torres, and D. Nathwani, Clinical and economic burden of community-acquired pneumonia among adults in Europe, Thorax. 1 janv, vol.67, issue.1, pp.71-80, 2012.

M. H. Rozenbaum, P. Pechlivanoglou, . Werf-ts-van-der, J. R. Lo-ten-foe, M. J. Postma et al., The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis, Eur J Clin Microbiol Infect Dis. 14 déc, vol.32, issue.3, pp.305-321, 2012.

, Données épidémiologiques / Infections à pneumocoque / Maladies à prévention vaccinale / Maladies infectieuses / Dossiers thématiques / Accueil

D. Sur,

, Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

J. C. Paton, I. R. Toogood, R. A. Cockington, and D. Hansman, Antibody response to pneumococcal vaccine in children aged 5 to 15 years, Am J Dis Child. févr, vol.140, issue.2, pp.135-143, 1986.
DOI : 10.1001/archpedi.1986.02140160053031

A. Vila-corcoles, Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia?, The Lancet Infectious Diseases. 1 juill, vol.8, issue.7, pp.405-411, 2008.
DOI : 10.1016/s1473-3099(08)70134-8

F. Braido, M. Bellotti, D. Maria, A. Cazzola, M. Canonica et al., The role of Pneumococcal vaccine, Pulm Pharmacol Ther. août, vol.21, issue.4, pp.608-623, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00499155

W. H. Organization, 23-valent pneumococcal polysaccharide vaccine : WHO position paper = Vaccin antipneumococcique polyosidique 23-valent : Note de synthèse de l'OMS. Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire, vol.83, pp.373-84, 2008.

M. C. Rodriguez-barradas, D. M. Musher, C. Lahart, C. Lacke, J. Groover et al., Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine, J Infect Dis. mars, vol.165, issue.3, pp.553-559, 1992.

A. Sangil, M. Xercavins, M. Rodríguez-carballeira, M. Andrés, M. Riera et al., Impact of vaccination on invasive pneumococcal disease in adults with focus on the immunosuppressed, J Infect, vol.71, issue.4, pp.422-429, 2015.

K. Kawakami, H. Kishino, S. Kanazu, K. Takahashi, T. Iino et al., Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more p, p.60

, than 5 years does not affect the immunogenicity and safety in the Japanese elderly, Hum Vaccin Immunother. 26 mars, pp.1-8, 2018.

J. Gaillat, D. Zmirou, M. R. Mallaret, D. Rouhan, J. P. Bru et al., Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions, Rev Epidemiol Sante Publique, vol.33, issue.6, pp.437-481, 1985.

M. Tin-tin-htar, A. L. Stuurman, G. Ferreira, C. Alicino, K. Bollaerts et al., Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies, PLoS ONE, vol.12, issue.5, p.177985, 2017.

H. Kraicer-melamed, O. Donnell, S. Quach, and C. , The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis, Vaccine. 18 mars, vol.34, issue.13, pp.1540-50, 2016.

J. Estrada, M. Najera, N. Pounds, G. Catano, and A. J. Infante, Clinical and Serologic Response to the 23-valent Polysaccharide Pneumococcal Vaccine in Children and Teens with Recurrent Upper Respiratory Tract Infections and Selective Antibody Deficiency, Pediatr Infect Dis J. févr, vol.35, issue.2, pp.205-213, 2016.

C. Remschmidt, T. Harder, O. Wichmann, C. Bogdan, and G. Falkenhorst,

, Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review, BMC Infect Dis, vol.25, issue.1, p.711, 2016.

M. Bonten, S. M. Huijts, M. Bolkenbaas, C. Webber, S. Patterson et al.,

, Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults, N Engl J Med. 19 mars, vol.372, issue.12, pp.1114-1139, 2015.

S. S. Richter, D. J. Diekema, K. P. Heilmann, C. L. Dohrn, F. Riahi et al., Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States, Antimicrob Agents Chemother, vol.58, issue.11, pp.6484-6493, 2014.

C. Savulescu, P. Krizova, A. Lepoutre, J. Mereckiene, D. F. Vestrheim et al., Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study, Lancet Respir Med, vol.5, issue.8, pp.648-56, 2017.

V. Baldo, S. Cocchio, T. Gallo, P. Furlan, P. Romor et al.,

, Pneumococcal Conjugated Vaccine Reduces the High Mortality for CommunityAcquired Pneumonia in the Elderly: an Italian Regional Experience, PLoS ONE, vol.11, issue.11, p.166637, 2016.

A. P. Desai, D. Sharma, E. K. Crispell, W. Baughman, S. Thomas et al., Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Pediatr Infect Dis J. nov, vol.34, issue.11, pp.1168-74, 2015.

D. M. Musher, A. M. Rueda, M. H. Nahm, E. A. Graviss, and M. C. Rodriguez-barradas, Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia, J Infect Dis, vol.198, issue.7, pp.1019-1046, 2008.

F. Lombardi, S. Belmonti, M. Fabbiani, M. Morandi, B. Rossetti et al., Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study, PLoS ONE, vol.11, issue.6, p.156523, 2016.

K. Kawakami, H. Kishino, S. Kanazu, N. Toshimizu, K. Takahashi et al., Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses, Vaccine, vol.19, issue.33, pp.3875-81, 2016.

J. Duffy, E. Weintraub, S. J. Hambidge, L. A. Jackson, E. O. Kharbanda et al., Febrile Seizure Risk After Vaccination in Children 6 to 23 Months, Pediatrics. juill, vol.138, issue.1, 2016.

M. Agier, S. Marchand, N. Paret, S. Gautier, and A. Jonville-béra, Bilan français des effets indésirables du vaccin Prévenar 13®, vol.24, pp.439-483, 2017.

. Varon-e and L. Gutmann, Epidémiologie de la résistance aux antibiotiques des pneumocoques, Rev Med Suisse, 2004.

D. Sur,

, Vaccination contre les infections invasives à pneumocoque avec le vaccin pneumococcique conjuqué 13-valent, Rapport [Internet] HCSP -Haut Conseil de Santé Publique, 2009.

D. Sur,

. Varon-e, Rapport d'activité 2016. Cent Natl Réf Pneumoc Paris

A. P. Desai, D. Sharma, E. K. Crispell, W. Baughman, S. Thomas et al., Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Pediatr Infect Dis J. nov, vol.34, issue.11, pp.1168-74, 2015.

, European Centre for Disease Prevention and Control, 2017.

D. Sur,

, Infections à pneumocoque : recommandations vaccinales pour les adultes [Internet] HCSP -Haut Conseil de Santé Publique, 2017.

S. Pouplin and G. Boulfroy, Le médecin généraliste picard face aux vaccinations en, 2016.

, Pneumocoque / Données / Couverture vaccinale / Maladies à prévention vaccinale / Maladies infectieuses / Dossiers thématiques / Accueil

D. Sur,

M. Mbesse-amakene and S. Nappez, Attitudes et freins du médecin généraliste à propos de la vaccination antipneumococcique des patients immunodéprimés: enquête qualitative réalisée auprès de 13 médecins généralistes de la Somme, 2017.

L. Andriantafika, Evaluation et pratique des médecins généralistes à propos de la vaccination anti-pneumococcique à 23 valences chez l'adulte en Picardie, 2013.

M. Bahuaud, C. Beaudouin-bazire, M. Husson, A. Molto, O. Launay et al., Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis, Hum Vaccin Immunother. 12 févr, pp.1-7, 2018.

A. M. Nishikawa, A. Sartori, G. M. Mainardi, A. C. Freitas, A. Itria et al., Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older, Vaccine, vol.03, issue.19, pp.2510-2532, 2018.

D. Thorrington, L. Van-rossum, M. Knol, H. De-melker, H. Rümke et al., Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands, PLoS ONE, vol.13, issue.2, p.192640, 2018.

Y. Jiang, X. Yang, K. Taniguchi, T. Petigara, and M. Abe, A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan, J Med Econ. 3 mai, pp.1-11, 2018.

D. Thorrington, N. Andrews, J. Stowe, E. Miller, and A. J. Van-hoek, Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control, BMC Med, vol.08, issue.1, p.13, 2018.

A. D. Protasov, A. V. Zhestkov, M. P. Kostinov, M. L. Shteiner, Y. V. Tezikov et al., Analysis of the effectiveness and long-term results of formation of adaptive immunity in the use of various medications and vaccination schemes against pneumococcal infection

, Ter Arkh, vol.89, issue.12, pp.165-74, 2017.

Z. Clark and D. Maurer, Pneumococcal Vaccines in Chronic Obstructive Pulmonary Disease, AFP. 1 avr, vol.97, issue.7, pp.463-467, 2018.

V. Lennep and F. , Vaccinations : attitudes et pratiques des médecins généralistes ÉTUDES et RÉSULTATS n° 910 -mars 2015 [Internet] Riposa C. mars 2015

N. Roche, E. Blanchard, J. Piquet, D. Piperno, C. Pinet et al., Enquête sur les attitudes vaccinales des pneumologues dans la BPCO. Focus sur la vaccination antipneumococcique, Revue des Maladies Respiratoires. 1 janv, vol.35, p.198, 2018.
DOI : 10.1016/j.rmr.2017.10.449

L. Herer, Impact du conseil hospitalier sur la vaccination antipneumococcique des adultes à risques par leurs médecins généralistes, pp.2011-50

B. Huguet, Pratique et suivi des modalités de la vaccination anti pneumococcique par les médecins généralistes chez les adultes depuis la mise à jour du calendrier vaccinal en mai, 2012.

R. L. Burton, H. W. Kim, S. Lee, H. Kim, J. Seok et al., Creation, characterization, and assignment of opsonic values for a new pneumococcal OPA calibration serum panel (Ewha QC sera panel A) for 13 serotypes, Medicine (Baltimore). avr, vol.97, issue.17, p.567, 2018.